July 6, 2020 07:28 AM EDTUpdated 11:04 AM

Covid-19 roundup: Teamed up with NIH, Regeneron launches PhIII prevention trial for antibody cocktail

Amber Tong

John Carroll

Editor & Founder

As Regeneron moves its antibody cocktail into Phase II/III trials testing REGN-COV2 as a treatment for both hospitalized and non-hospitalized patients with Covid-19, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Teamed up with NIH, Regeneron launches PhIII prevention trial for antibody cocktail

Amber Tong

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

Covid-19 roundup: Teamed up with NIH, Re­gen­eron launch­es PhI­II pre­ven­tion tri­al for an­ti­body cock­tail

Editor & Founder

Sign up to read this article for free.

more like this

Covid-19 roundup: Teamed up with NIH, Regeneron launches PhIII prevention trial for antibody cocktail